CAT-09-833

CAT-09-833 is a preclinical **MUC1-targeting antibody-drug conjugate** being developed by Catalent using its SMARTag platform for solid tumors, with public descriptions highlighting **platinum-resistant ovarian carcinoma** as the lead indication. Available public-source descriptions characterize it as a tumor-selective anti-MUC1 ADC with encouraging preclinical efficacy and tolerability; however, the exact antibody sequence, payload, linker composition, and precise target epitope details have not been clearly disclosed in the public materials identified. Based on the available information, its intended mechanism is selective binding to **Mucin-1**-expressing tumor cells followed by ADC-mediated delivery of a cytotoxic payload to drive antitumor activity.